Litcius/Paper detail

Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase

Sébastien L. Degorce, Omid Tavana, Erica Banks, Claire Crafter, Lakshmaiah Gingipalli, David Kouvchinov, Yumeng Mao, Fiona Pachl, Anisha Solanki, Viia Valge-Archer, Bin Yang, Scott D. Edmondson

2020Journal of Medicinal Chemistry50 citationsDOIOpen Access PDF

Abstract

We report the first disclosure of IRAK3 degraders in the scientific literature. Taking advantage of an opportune byproduct obtained during our efforts to identify IRAK4 inhibitors, we identified ready-to-use, selective IRAK3 ligands in our compound collection with the required properties for conversion into proteolysis-targeting chimera (PROTAC) degraders. This work culminated with the discovery of PROTAC 23, which we demonstrated to be a potent and selective degrader of IRAK3 after 16 h in THP1 cells. 23 induced proteasome-dependent degradation of IRAK3 and required both CRBN and IRAK3 binding for activity. We conclude that PROTAC 23 constitutes an excellent in vitro tool with which to interrogate the biology of IRAK3.

Topics & Concepts

ProteolysisChemistryChimera (genetics)ProteasomeIn vitroUbiquitinProtein degradationSmall moleculeBiochemistryComputational biologyCell biologyEnzymeBiologyGeneProtein Degradation and InhibitorsUbiquitin and proteasome pathwaysPeptidase Inhibition and Analysis